DCGI seeks clarification from Glenmark on its anti-viral favipiravir for use on COVID-19 patients
Jul 19, 2020
New Delhi [India], July 19 : The Drugs Controller General of India (DCGI) has asked for a clarification from Glenmark Pharmaceuticals regarding its alleged "false claims" on the utilisation of anti-viral FabiFlu (favipiravir) on COVID-19 patients with comorbidities.